Resveratrol
- Generic Name
- Resveratrol
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C14H12O3
- CAS Number
- 501-36-0
- Unique Ingredient Identifier
- Q369O8926L
- Background
Resveratrol (3,5,4'-trihydroxystilbene) is a polyphenolic phytoalexin. It is a stilbenoid, a derivate of stilbene, and is produced in plants with the help of the enzyme stilbene synthase. It exists as cis-(Z) and trans-(E) isomers. The trans- form can undergo isomerisation to the cis- form when heated or exposed to ultraviolet irradiation. In a 2004 issue of...
- Indication
Being investigated for the treatment of Herpes labialis infections (cold sores).
- Associated Conditions
- -
- Associated Therapies
- -
Resveratrol in Postmenopausal Women With High Body Mass Index
- Conditions
- Interventions
- First Posted Date
- 2011-06-10
- Last Posted Date
- 2014-10-09
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 46
- Registration Number
- NCT01370889
- Locations
- πΊπΈ
Arizona Cancer Center - Tucson, Tucson, Arizona, United States
πΊπΈUniversity of Arizona Health Sciences Center, Tucson, Arizona, United States
Effect of Resveratrol on Age-related Insulin Resistance and Inflammation in Humans
- First Posted Date
- 2011-05-17
- Last Posted Date
- 2022-03-08
- Lead Sponsor
- Albert Einstein College of Medicine
- Target Recruit Count
- 20
- Registration Number
- NCT01354977
- Locations
- πΊπΈ
Albert Einstein College of Medicine, Bronx, New York, United States
A Study of Resveratrol as Treatment for Friedreich Ataxia
- First Posted Date
- 2011-04-21
- Last Posted Date
- 2014-01-22
- Lead Sponsor
- Murdoch Childrens Research Institute
- Target Recruit Count
- 27
- Registration Number
- NCT01339884
- Locations
- π¦πΊ
Monash Medical Centre, Southern Health, Clayton, Melbourne, Victoria, Australia
Use of Resveratrol to Decrease Acute Secondary Brain Injury Following Sports-Related Concussions in Boxers
- First Posted Date
- 2011-03-23
- Last Posted Date
- 2021-02-11
- Lead Sponsor
- University of Texas Southwestern Medical Center
- Target Recruit Count
- 12
- Registration Number
- NCT01321151
- Locations
- πΊπΈ
University of Texas Southwestern Medical Center, Dallas, Texas, United States
Resveratrol in Healthy Adult Participants
- Conditions
- Interventions
- First Posted Date
- 2008-07-25
- Last Posted Date
- 2014-10-08
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 42
- Registration Number
- NCT00721877
- Locations
- πΊπΈ
Arizona Cancer Center - Tucson, Tucson, Arizona, United States
Mechanisms of Metabolic Regulation of Resveratrol on Humans With Metabolic Syndrome
- First Posted Date
- 2008-04-09
- Last Posted Date
- 2015-03-04
- Lead Sponsor
- University of California, San Francisco
- Registration Number
- NCT00654667
- Locations
- πΊπΈ
University of California, San Francisco, California, United States
Resveratrol in Treating Patients With Colorectal Cancer That Can Be Removed By Surgery
- Conditions
- Interventions
- First Posted Date
- 2007-02-12
- Last Posted Date
- 2014-09-15
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 20
- Registration Number
- NCT00433576
- Locations
- πΊπΈ
University of Michigan, Ann Arbor, Michigan, United States
Resveratrol for Patients With Colon Cancer
- First Posted Date
- 2005-11-21
- Last Posted Date
- 2014-06-20
- Lead Sponsor
- University of California, Irvine
- Target Recruit Count
- 11
- Registration Number
- NCT00256334
- Locations
- πΊπΈ
Chao Family Comprehensive Cancer Center, Orange, California, United States
UMCC 2003-064 Resveratrol in Preventing Cancer in Healthy Participants
- Conditions
- First Posted Date
- 2004-12-09
- Last Posted Date
- 2012-12-17
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 40
- Registration Number
- NCT00098969
- Locations
- πΊπΈ
University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
π¬π§Leicester Royal Infirmary, Leicester, England, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.